Congenital factor XIII deficiency is a rare disorder that leads to abnormal bleeding and poor wound healing due to inefficient clot stabilization. This disease affects 1 in every 2-3 million live births. Diagnosing Factor XIII deficiency demands a high degree of clinical suspicion and precise laboratory analysis. Current treatment strategies have evolved to include fresh frozen plasma and cryoprecipitate, with recent advances in prophylactic therapies using factor XIII concentrate and recombinant factor XIII.
1 Glanzmann's thrombasthenia (GT) is caused due to a deficiency in the α-IIb β3 platelet integrin, leading to bleeding episodes, especially in mucocutaneous areas. With a global rarity of one in a million, GT challenges clinicians with its management, which is categorized by severity and treatment responsiveness. This condition calls for a nuanced approach, from preventive…
